Surgical management of peritoneal metastasis: Opportunities for pharmaceutical research
Cytoreductive surgery (CRS) has emerged as a survival-extending treatment of peritoneal metastasis (PM); recent advances include using intraperitoneal chemotherapy (IPC) at normothermic or hyperthermic temperatures, or under pressure (CRS + IPC). Clinical CRS + IPC research has established its highl...
Uloženo v:
| Vydáno v: | Journal of controlled release Ročník 361; s. 717 - 726 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Netherlands
Elsevier B.V
01.09.2023
|
| Témata: | |
| ISSN: | 0168-3659, 1873-4995, 1873-4995 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Cytoreductive surgery (CRS) has emerged as a survival-extending treatment of peritoneal metastasis (PM); recent advances include using intraperitoneal chemotherapy (IPC) at normothermic or hyperthermic temperatures, or under pressure (CRS + IPC). Clinical CRS + IPC research has established its highly variable efficacy and suggested tumor size, tumor locations and presence of ascites as potential determinants. On the other hand, there is limited knowledge on the effects of pharmaceutical properties on treatment outcomes. The present study investigated the inter-subject variability of paclitaxel binding to proteins in patient ascites because some PM patients show accumulation of ascites and because activity and transport of highly protein-bound drugs such as paclitaxel are affected by protein binding.
Ascites samples were collected from 26 patients and investigated for their protein contents using LC/MS/MS proteomics analysis and for the concentrations of total proteins and two major paclitaxel-binding proteins (human serum albumin or HSA and α-1-acid glycoprotein or AAG). The association constants of paclitaxel to HSA and AAG and the extent of protein binding of paclitaxel in patient ascites were studied using equilibrium dialysis.
Proteomic analysis of four randomly selected samples revealed 288 proteins, >90% of which are also present in human plasma. Between 72% - 94% of paclitaxel was bound to proteins in patient ascites. The concentrations of HSA and AAG in ascites showed substantial inter-subject variations, ranging from 14.7 – 46.3 mg/mL and 0.13–2.56 mg/mL, respectively. The respective paclitaxel association constants to commercially available HSA and AAG were ∼ 3.5 and ∼ 120 mM. Calculation using these constants and the HSA and AAG concentrations in individual patient ascites indicated that these two proteins accounted for >85% of the total protein-binding of paclitaxel in ascites. The extensive drug binding to ascites proteins, by reducing the pharmacologically active free fraction, may lead to the diminished CRS efficacy in PM patients with ascites.
Clinical advances in CRS + IPC have outpaced current knowledge of pharmaceutical properties in this setting. IPC, as a locally acting therapy, is subjected to processes different from those governing systemic treatments. This study, to our knowledge, is the first to illustrate the implications of drug properties in the CRS + IPC efficacy against PM. While drugs are now an integral part of PM patient management, there is limited pharmaceutical research in this treatment setting (e.g., effects of hyperthermia or pressure on drug transport or release from delivery systems, pharmacokinetics, pharmacodynamics). Hence, CRS + IPC of PM represents an area where additional pharmaceutical research can assist further development and optimization.
[Display omitted]
•Peritoneal metastasis is managed by surgery+intraperitoneal chemotherapy (CRS + IPC).•IPC efficacy against peritoneal metastasis appears lowered by presence of ascites.•Extensive protein binding of paclitaxel reduces % active free drug in patient ascites.•Albumin and α-1-acid glycoprotein account for >85% paclitaxel binding in ascites.•Current study is an example on using pharmaceutical research to optimize CRS + IPC. |
|---|---|
| AbstractList | Cytoreductive surgery (CRS) has emerged as a survival-extending treatment of peritoneal metastasis (PM); recent advances include using intraperitoneal chemotherapy (IPC) at normothermic or hyperthermic temperatures, or under pressure (CRS+IPC). Clinical CRS+IPC research has established its highly variable efficacy and suggested tumor size, tumor locations and presence of ascites as potential determinants. On the other hand, there is limited knowledge on the effects of pharmaceutical properties on treatment outcomes. The present study investigated the inter-subject variability of paclitaxel binding to proteins in patient ascites because some PM patients show accumulation of ascites and because activity and transport of highly protein-bound drugs such as paclitaxel are affected by protein binding. Ascites samples were collected from 26 patients and investigated for their protein contents using LC/MS/MS proteomics analysis and for the concentrations of total proteins and two major paclitaxel-binding proteins (human serum albumin or HSA and α-1-acid glycoprotein or AAG). The association constants of paclitaxel to HSA and AAG and the extent of protein binding of paclitaxel in patient ascites were studied using equilibrium dialysis. Proteomic analysis of four randomly selected samples revealed 288 proteins, >90% of which are also present in human plasma. Between 72% to 94% of paclitaxel was bound to proteins in patient ascites. The concentrations of HSA and AAG in ascites showed substantial inter-subject variations, ranging from 14.7-46.3 mg/ml and 0.13-2.56 mg/ml, respectively. The respective paclitaxel association constants to commercially available HSA and AAG were ~3.5 and ~120 mM. Calculation using these constants and the HSA and AAG concentrations in individual patient ascites indicated that these two proteins accounted for >85% of the total protein-binding of paclitaxel in ascites. The extensive drug binding to ascites proteins, by reducing the pharmacologically active free fraction, may lead to the diminished CRS efficacy in PM patients with ascites. Clinical advances in CRS+IPC have outpaced current knowledge of pharmaceutical properties in this setting. IPC, as a locally acting therapy, is subjected to processes different from those governing systemic treatments. This study, to our knowledge, is the first to illustrate the implications of drug properties in the CRS+IPC efficacy against PM. While drugs are now an integral part of PM patient management, there is limited pharmaceutical research in this treatment setting (e.g., effects of hyperthermia or pressure on drug transport or release from delivery systems, pharmacokinetics, pharmacodynamics). Hence, CRS+IPC of PM represents an area where additional pharmaceutical research can assist further development and optimization. Cytoreductive surgery (CRS) has emerged as a survival-extending treatment of peritoneal metastasis (PM); recent advances include using intraperitoneal chemotherapy (IPC) at normothermic or hyperthermic temperatures, or under pressure (CRS + IPC). Clinical CRS + IPC research has established its highly variable efficacy and suggested tumor size, tumor locations and presence of ascites as potential determinants. On the other hand, there is limited knowledge on the effects of pharmaceutical properties on treatment outcomes. The present study investigated the inter-subject variability of paclitaxel binding to proteins in patient ascites because some PM patients show accumulation of ascites and because activity and transport of highly protein-bound drugs such as paclitaxel are affected by protein binding. Ascites samples were collected from 26 patients and investigated for their protein contents using LC/MS/MS proteomics analysis and for the concentrations of total proteins and two major paclitaxel-binding proteins (human serum albumin or HSA and α-1-acid glycoprotein or AAG). The association constants of paclitaxel to HSA and AAG and the extent of protein binding of paclitaxel in patient ascites were studied using equilibrium dialysis. Proteomic analysis of four randomly selected samples revealed 288 proteins, >90% of which are also present in human plasma. Between 72% to 94% of paclitaxel was bound to proteins in patient ascites. The concentrations of HSA and AAG in ascites showed substantial inter-subject variations, ranging from 14.7 to 46.3 mg/ml and 0.13–2.56 mg/ml, respectively. The respective paclitaxel association constants to commercially available HSA and AAG were ~ 3.5 and ~ 120 mM. Calculation using these constants and the HSA and AAG concentrations in individual patient ascites indicated that these two proteins accounted for >85% of the total protein-binding of paclitaxel in ascites. The extensive drug binding to ascites proteins, by reducing the pharmacologically active free fraction, may lead to the diminished CRS efficacy in PM patients with ascites. Clinical advances in CRS + IPC have outpaced current knowledge of pharmaceutical properties in this setting. IPC, as a locally acting therapy, is subjected to processes different from those governing systemic treatments. This study, to our knowledge, is the first to illustrate the implications of drug properties in the CRS + IPC efficacy against PM. While drugs are now an integral part of PM patient management, there is limited pharmaceutical research in this treatment setting (e.g., effects of hyperthermia or pressure on drug transport or release from delivery systems, pharmacokinetics, pharmacodynamics). Hence, CRS + IPC of PM represents an area where additional pharmaceutical research can assist further development and optimization. Cytoreductive surgery (CRS) has emerged as a survival-extending treatment of peritoneal metastasis (PM); recent advances include using intraperitoneal chemotherapy (IPC) at normothermic or hyperthermic temperatures, or under pressure (CRS + IPC). Clinical CRS + IPC research has established its highly variable efficacy and suggested tumor size, tumor locations and presence of ascites as potential determinants. On the other hand, there is limited knowledge on the effects of pharmaceutical properties on treatment outcomes. The present study investigated the inter-subject variability of paclitaxel binding to proteins in patient ascites because some PM patients show accumulation of ascites and because activity and transport of highly protein-bound drugs such as paclitaxel are affected by protein binding. Ascites samples were collected from 26 patients and investigated for their protein contents using LC/MS/MS proteomics analysis and for the concentrations of total proteins and two major paclitaxel-binding proteins (human serum albumin or HSA and α-1-acid glycoprotein or AAG). The association constants of paclitaxel to HSA and AAG and the extent of protein binding of paclitaxel in patient ascites were studied using equilibrium dialysis. Proteomic analysis of four randomly selected samples revealed 288 proteins, >90% of which are also present in human plasma. Between 72% - 94% of paclitaxel was bound to proteins in patient ascites. The concentrations of HSA and AAG in ascites showed substantial inter-subject variations, ranging from 14.7 - 46.3 mg/mL and 0.13-2.56 mg/mL, respectively. The respective paclitaxel association constants to commercially available HSA and AAG were ∼ 3.5 and ∼ 120 mM. Calculation using these constants and the HSA and AAG concentrations in individual patient ascites indicated that these two proteins accounted for >85% of the total protein-binding of paclitaxel in ascites. The extensive drug binding to ascites proteins, by reducing the pharmacologically active free fraction, may lead to the diminished CRS efficacy in PM patients with ascites. Clinical advances in CRS + IPC have outpaced current knowledge of pharmaceutical properties in this setting. IPC, as a locally acting therapy, is subjected to processes different from those governing systemic treatments. This study, to our knowledge, is the first to illustrate the implications of drug properties in the CRS + IPC efficacy against PM. While drugs are now an integral part of PM patient management, there is limited pharmaceutical research in this treatment setting (e.g., effects of hyperthermia or pressure on drug transport or release from delivery systems, pharmacokinetics, pharmacodynamics). Hence, CRS + IPC of PM represents an area where additional pharmaceutical research can assist further development and optimization.Cytoreductive surgery (CRS) has emerged as a survival-extending treatment of peritoneal metastasis (PM); recent advances include using intraperitoneal chemotherapy (IPC) at normothermic or hyperthermic temperatures, or under pressure (CRS + IPC). Clinical CRS + IPC research has established its highly variable efficacy and suggested tumor size, tumor locations and presence of ascites as potential determinants. On the other hand, there is limited knowledge on the effects of pharmaceutical properties on treatment outcomes. The present study investigated the inter-subject variability of paclitaxel binding to proteins in patient ascites because some PM patients show accumulation of ascites and because activity and transport of highly protein-bound drugs such as paclitaxel are affected by protein binding. Ascites samples were collected from 26 patients and investigated for their protein contents using LC/MS/MS proteomics analysis and for the concentrations of total proteins and two major paclitaxel-binding proteins (human serum albumin or HSA and α-1-acid glycoprotein or AAG). The association constants of paclitaxel to HSA and AAG and the extent of protein binding of paclitaxel in patient ascites were studied using equilibrium dialysis. Proteomic analysis of four randomly selected samples revealed 288 proteins, >90% of which are also present in human plasma. Between 72% - 94% of paclitaxel was bound to proteins in patient ascites. The concentrations of HSA and AAG in ascites showed substantial inter-subject variations, ranging from 14.7 - 46.3 mg/mL and 0.13-2.56 mg/mL, respectively. The respective paclitaxel association constants to commercially available HSA and AAG were ∼ 3.5 and ∼ 120 mM. Calculation using these constants and the HSA and AAG concentrations in individual patient ascites indicated that these two proteins accounted for >85% of the total protein-binding of paclitaxel in ascites. The extensive drug binding to ascites proteins, by reducing the pharmacologically active free fraction, may lead to the diminished CRS efficacy in PM patients with ascites. Clinical advances in CRS + IPC have outpaced current knowledge of pharmaceutical properties in this setting. IPC, as a locally acting therapy, is subjected to processes different from those governing systemic treatments. This study, to our knowledge, is the first to illustrate the implications of drug properties in the CRS + IPC efficacy against PM. While drugs are now an integral part of PM patient management, there is limited pharmaceutical research in this treatment setting (e.g., effects of hyperthermia or pressure on drug transport or release from delivery systems, pharmacokinetics, pharmacodynamics). Hence, CRS + IPC of PM represents an area where additional pharmaceutical research can assist further development and optimization. Cytoreductive surgery (CRS) has emerged as a survival-extending treatment of peritoneal metastasis (PM); recent advances include using intraperitoneal chemotherapy (IPC) at normothermic or hyperthermic temperatures, or under pressure (CRS + IPC). Clinical CRS + IPC research has established its highly variable efficacy and suggested tumor size, tumor locations and presence of ascites as potential determinants. On the other hand, there is limited knowledge on the effects of pharmaceutical properties on treatment outcomes. The present study investigated the inter-subject variability of paclitaxel binding to proteins in patient ascites because some PM patients show accumulation of ascites and because activity and transport of highly protein-bound drugs such as paclitaxel are affected by protein binding. Ascites samples were collected from 26 patients and investigated for their protein contents using LC/MS/MS proteomics analysis and for the concentrations of total proteins and two major paclitaxel-binding proteins (human serum albumin or HSA and α-1-acid glycoprotein or AAG). The association constants of paclitaxel to HSA and AAG and the extent of protein binding of paclitaxel in patient ascites were studied using equilibrium dialysis. Proteomic analysis of four randomly selected samples revealed 288 proteins, >90% of which are also present in human plasma. Between 72% - 94% of paclitaxel was bound to proteins in patient ascites. The concentrations of HSA and AAG in ascites showed substantial inter-subject variations, ranging from 14.7 - 46.3 mg/mL and 0.13-2.56 mg/mL, respectively. The respective paclitaxel association constants to commercially available HSA and AAG were ∼ 3.5 and ∼ 120 mM. Calculation using these constants and the HSA and AAG concentrations in individual patient ascites indicated that these two proteins accounted for >85% of the total protein-binding of paclitaxel in ascites. The extensive drug binding to ascites proteins, by reducing the pharmacologically active free fraction, may lead to the diminished CRS efficacy in PM patients with ascites. Clinical advances in CRS + IPC have outpaced current knowledge of pharmaceutical properties in this setting. IPC, as a locally acting therapy, is subjected to processes different from those governing systemic treatments. This study, to our knowledge, is the first to illustrate the implications of drug properties in the CRS + IPC efficacy against PM. While drugs are now an integral part of PM patient management, there is limited pharmaceutical research in this treatment setting (e.g., effects of hyperthermia or pressure on drug transport or release from delivery systems, pharmacokinetics, pharmacodynamics). Hence, CRS + IPC of PM represents an area where additional pharmaceutical research can assist further development and optimization. Cytoreductive surgery (CRS) has emerged as a survival-extending treatment of peritoneal metastasis (PM); recent advances include using intraperitoneal chemotherapy (IPC) at normothermic or hyperthermic temperatures, or under pressure (CRS + IPC). Clinical CRS + IPC research has established its highly variable efficacy and suggested tumor size, tumor locations and presence of ascites as potential determinants. On the other hand, there is limited knowledge on the effects of pharmaceutical properties on treatment outcomes. The present study investigated the inter-subject variability of paclitaxel binding to proteins in patient ascites because some PM patients show accumulation of ascites and because activity and transport of highly protein-bound drugs such as paclitaxel are affected by protein binding. Ascites samples were collected from 26 patients and investigated for their protein contents using LC/MS/MS proteomics analysis and for the concentrations of total proteins and two major paclitaxel-binding proteins (human serum albumin or HSA and α-1-acid glycoprotein or AAG). The association constants of paclitaxel to HSA and AAG and the extent of protein binding of paclitaxel in patient ascites were studied using equilibrium dialysis. Proteomic analysis of four randomly selected samples revealed 288 proteins, >90% of which are also present in human plasma. Between 72% - 94% of paclitaxel was bound to proteins in patient ascites. The concentrations of HSA and AAG in ascites showed substantial inter-subject variations, ranging from 14.7 – 46.3 mg/mL and 0.13–2.56 mg/mL, respectively. The respective paclitaxel association constants to commercially available HSA and AAG were ∼ 3.5 and ∼ 120 mM. Calculation using these constants and the HSA and AAG concentrations in individual patient ascites indicated that these two proteins accounted for >85% of the total protein-binding of paclitaxel in ascites. The extensive drug binding to ascites proteins, by reducing the pharmacologically active free fraction, may lead to the diminished CRS efficacy in PM patients with ascites. Clinical advances in CRS + IPC have outpaced current knowledge of pharmaceutical properties in this setting. IPC, as a locally acting therapy, is subjected to processes different from those governing systemic treatments. This study, to our knowledge, is the first to illustrate the implications of drug properties in the CRS + IPC efficacy against PM. While drugs are now an integral part of PM patient management, there is limited pharmaceutical research in this treatment setting (e.g., effects of hyperthermia or pressure on drug transport or release from delivery systems, pharmacokinetics, pharmacodynamics). Hence, CRS + IPC of PM represents an area where additional pharmaceutical research can assist further development and optimization. [Display omitted] •Peritoneal metastasis is managed by surgery+intraperitoneal chemotherapy (CRS + IPC).•IPC efficacy against peritoneal metastasis appears lowered by presence of ascites.•Extensive protein binding of paclitaxel reduces % active free drug in patient ascites.•Albumin and α-1-acid glycoprotein account for >85% paclitaxel binding in ascites.•Current study is an example on using pharmaceutical research to optimize CRS + IPC. |
| Author | Chan, Carlos H.F. Au, Jessie L.S. Wientjes, Michael G. Lu, Ze Turaga, Kiran |
| AuthorAffiliation | e College of Pharmacy, Taipei Medical University, Taipei, Taiwan d Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA a Institute of Quantitative Systems Pharmacology, Carlsbad, CA 92008, USA b Department of Surgery and Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA c School of Medicine, Yale University, New Haven, CT 06520, USA |
| AuthorAffiliation_xml | – name: d Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA – name: a Institute of Quantitative Systems Pharmacology, Carlsbad, CA 92008, USA – name: c School of Medicine, Yale University, New Haven, CT 06520, USA – name: e College of Pharmacy, Taipei Medical University, Taipei, Taiwan – name: b Department of Surgery and Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA |
| Author_xml | – sequence: 1 givenname: Michael G. surname: Wientjes fullname: Wientjes, Michael G. organization: Institute of Quantitative Systems Pharmacology, Carlsbad, CA 92008, USA – sequence: 2 givenname: Ze surname: Lu fullname: Lu, Ze organization: Institute of Quantitative Systems Pharmacology, Carlsbad, CA 92008, USA – sequence: 3 givenname: Carlos H.F. surname: Chan fullname: Chan, Carlos H.F. organization: Department of Surgery and Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA – sequence: 4 givenname: Kiran surname: Turaga fullname: Turaga, Kiran organization: School of Medicine, Yale University, New Haven, CT 06520, USA – sequence: 5 givenname: Jessie L.S. surname: Au fullname: Au, Jessie L.S. email: jau@i-qsp.org organization: Institute of Quantitative Systems Pharmacology, Carlsbad, CA 92008, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37574051$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkV-L1DAUxYOsuLOjH0Hpoy-tN03TZPRBZPEfLOyDio8hTW9nMrRJTdIFv72pOyvqy0AgD_fcc3-cc0UunHdIyHMKFQXavjpWR-NdwLGqoWYVyAqoeEQ2VApWNrsdvyCbrJMla_nuklzFeAQAzhrxhFwywUUDnG7I9y9L2Fujx2LSTu9xQpcKPxQzBpvyxXWAScf8bHxd3M6zD2lxNlmMxeBDMR90mLTBJf12CRhRB3N4Sh4Peoz47PRvybcP779efypvbj9-vn53UxoONJUCsae07qg0THaUwW7odAs1tn0nqWCCga5F0yJtQZia1o1suGzBSMHlIIBtydt733npJuxNxg96VHOwkw4_lddW_Ttx9qD2_k5R4C1Aszq8PDkE_2PBmNRko8Fx1A79EhXLoqapM8xZaS05CMp5jnlLXvzN9QfoIfkseHMvMMHHGHBQxiadrF8x7Zj51NqzOqpTz2rtWYFUuee8zf_bfjhwbu8UF-ZO7iwGFY1FZ7C3AU1SvbdnHH4B6GvGBQ |
| CitedBy_id | crossref_primary_10_1016_j_jconrel_2024_10_011 |
| Cites_doi | 10.3923/ijp.2006.293.297 10.1007/BF01062207 10.1016/0378-4347(94)00456-F 10.3389/fimmu.2012.00217 10.1007/BF00684852 10.1006/gyno.1999.5677 10.1200/JCO.2003.04.187 10.1245/s10434-006-9185-7 10.1016/S0272-6386(12)81084-5 10.1021/acs.chemrev.8b00042 10.1038/nm1523 10.1007/s002800050973 10.1245/s10434-014-3798-z 10.1111/j.1365-2125.1985.tb05107.x 10.3390/ph14020104 10.3390/ijms19103028 10.1093/annonc/mdy551 10.7554/eLife.23190 10.1021/cr3003533 10.1007/s00280-015-2737-4 10.1200/JCO.2014.55.9898 10.1126/scitranslmed.aba6110 10.1002/jps.21317 10.1016/S0923-7534(20)31486-1 10.1245/s10434-013-3213-1 10.3390/cells7100147 10.1371/journal.pone.0101694 10.1200/JCO.2018.36.18_suppl.LBA3503 10.1148/107.3.577 10.1073/pnas.1906986116 10.3322/caac.21763 10.1080/10717544.2019.1704945 10.1007/BF00685503 10.1007/BF01410140 10.1186/s12885-020-06964-5 10.1016/j.devcel.2019.03.026 10.4155/bio.11.187 10.1006/gyno.1993.1171 10.3389/fphy.2019.00045 10.1016/j.immuni.2015.11.024 10.1200/JCO.2001.19.4.1001 10.1016/j.ebiom.2022.104151 10.1093/annonc/mdx451 10.1200/JCO.1992.10.9.1485 10.1245/s10434-020-08842-7 10.3389/fonc.2021.650098 10.1200/JCO.18.01568 10.3390/jcm7120567 10.1200/JCO.2002.20.3.694 10.1007/BF00686048 10.1007/s00280-019-03767-9 10.1200/JCO.2009.23.9285 10.3802/jgo.2020.31.e58 10.1021/js950286j 10.1074/jbc.REV119.007963 10.1007/BF00262740 10.1200/JCO.2018.77.8613 10.1146/annurev-immunol-032712-100008 10.1056/NEJM199612263352603 10.1016/j.ccell.2015.10.012 10.1056/NEJMoa1708618 10.1186/s40169-018-0202-9 10.1002/jps.2600730617 10.1177/1758835918777036 10.1002/pmic.201100264 10.3389/fcell.2018.00017 10.1056/NEJMoa052985 10.4155/bio.13.338 |
| ContentType | Journal Article |
| Copyright | 2023 Elsevier B.V. Copyright © 2023 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2023 Elsevier B.V. – notice: Copyright © 2023 Elsevier B.V. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 5PM |
| DOI | 10.1016/j.jconrel.2023.08.017 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | AGRICOLA MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-4995 |
| EndPage | 726 |
| ExternalDocumentID | PMC10560040 37574051 10_1016_j_jconrel_2023_08_017 S0168365923005151 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCATS NIH HHS grantid: UL1 TR001863 – fundername: NCI NIH HHS grantid: P30 CA086862 – fundername: NIGMS NIH HHS grantid: R01 GM100487 |
| GroupedDBID | --- --K --M .GJ .~1 0R~ 1B1 1RT 1~. 1~5 29K 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AABNK AABXZ AACTN AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYOK ABFNM ABFRF ABJNI ABMAC ABOCM ABWVN ABXDB ABZDS ACDAQ ACGFO ACGFS ACIUM ACNNM ACRLP ACRPL ADBBV ADEZE ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEZYN AFJKZ AFRZQ AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AKRWK ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 CS3 D-I DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMT HVGLF HZ~ IHE J1W KOM M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG RNS ROL RPZ SCC SDF SDG SDP SES SEW SPC SPCBC SPT SSH SSM SSP SSZ T5K TEORI WUQ ~G- 9DU AAYWO AAYXX ACLOT ACVFH ADCNI AEUPX AFPUW AGQPQ AIGII AIIUN AKBMS AKYEP APXCP CITATION EFKBS EFLBG ~HD AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c501t-7eed112b18c38b1309fba602e6db8173730a2746e1607c2124845860c8758f703 |
| ISICitedReferencesCount | 1 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001067360500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0168-3659 1873-4995 |
| IngestDate | Tue Sep 30 17:09:17 EDT 2025 Thu Oct 02 21:42:34 EDT 2025 Sun Nov 09 10:26:08 EST 2025 Mon Jul 21 06:04:33 EDT 2025 Sat Nov 29 07:27:48 EST 2025 Tue Nov 18 21:47:20 EST 2025 Sun Apr 06 06:56:34 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | MCW CRS KHSA and KAAG Cbound and Cfree fu P PIPAC HIPEC UI Intraperitoneal chemotherapy Peritoneal carcinomatosis Paclitaxel HSA PBS R2 Cytoreductive surgery AAG IP Drug binding to ascites proteins ICD fb,measured fb,expected Hyperthermic intraperitoneal chemotherapy fb IPC PM |
| Language | English |
| License | Copyright © 2023 Elsevier B.V. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c501t-7eed112b18c38b1309fba602e6db8173730a2746e1607c2124845860c8758f703 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors made equal contribution. |
| OpenAccessLink | https://pmc.ncbi.nlm.nih.gov/articles/PMC10560040/pdf/nihms-1928389.pdf |
| PMID | 37574051 |
| PQID | 2850715505 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10560040 proquest_miscellaneous_3040442173 proquest_miscellaneous_2850715505 pubmed_primary_37574051 crossref_citationtrail_10_1016_j_jconrel_2023_08_017 crossref_primary_10_1016_j_jconrel_2023_08_017 elsevier_sciencedirect_doi_10_1016_j_jconrel_2023_08_017 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-09-01 |
| PublicationDateYYYYMMDD | 2023-09-01 |
| PublicationDate_xml | – month: 09 year: 2023 text: 2023-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Journal of controlled release |
| PublicationTitleAlternate | J Control Release |
| PublicationYear | 2023 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Galluzzi, Buqué, Kepp, Zitvogel, Kroemer (bb0465) 2015; 28 Elferink, van der Vijgh, Klein, Bokkel Huinink, Dubbelman, McVie (bb0045) 1988; 21 Speyer, Collins, Dedrick, Brennan, Buckpitt, Londer, DeVita, Myers (bb0055) 1980; 40 Feldman, Knapp, Order, Hellman (bb0235) 1972; 32 Northcott, Dean, Mouw, Weaver (bb0375) 2018; 6 Saitakis, Dogniaux, Goudot, Bufi, Asnacios, Maurin, Randriamampita, Asnacios, Hivroz (bb0410) 2017; 6 Armstrong, Bundy, Wenzel, Huang, Baergen, Lele, Copeland, Walker, Burger (bb0110) 2006; 354 Waters, Jones, Williams, Sohal (bb0330) 2008; 97 Tu, Pagliaro, Banks, Amato, Millikan, Bugazia, Madden, Newman, Logothetis (bb0460) 1998; 4 Reymond, Solass, Tempfer (bb0090) 2015 Buscher, Laakso, Mascher, Pusecker, Doig, Dillen, Wagner-Redeker, Pfeifer, Delrat, Timmerman (bb0335) 2014; 6 Chaudhuri, Low, Lim (bb0370) 2018; 118 Knemeyer, Wientjes, Au (bb0285) 1999; 44 Kroemer, Galluzzi, Kepp, Zitvogel (bb0435) 2013; 31 Ozols, Gore, Trope, Grenman (bb0155) 1999; 10 Chan, Lu, Wientjes, Au (bb0250) 2023 Dasgupta, McCollum (bb0380) 2019; 294 (bb0025) 2023 Markman, Bundy, Alberts, Fowler, Clark-Pearson, Carson, Wadler, Sickel (bb0115) 2001; 19 Esquivel, Sticca, Sugarbaker, Levine, Yan, Alexander, Baratti, Bartlett, Barone, Barrios, Bieligk, Bretcha-Boix, Chang, Chu, Chu, Daniel, Deraco, Dominguez-Parra, Elias, Flynn, Foster, Garofalo, Gilly, Glehen, Gomez-Portilla, Gonzalez-Bayon, Gonzalez-Moreno, Goodman, Gushchin, Hanna, Hartmann, Harrison, Hoefer, Kane, Kecmanovic, Kelley, Kuhn, Lamont, Lange, Li, Loggie, Mahteme, Mann, Martin, Misih, Moran, Morris, Onate-Ocana, Petrelli, Philippe, Pingpank, Pitroff, Piso, Quinones, Riley, Rutstein, Saha, Alrawi, Sardi, Schneebaum, Shen, Shibata, Spellman, Stojadinovic, Stewart, Torres-Melero, Tuttle, Verwaal, Villar, Wilkinson, Younan, Zeh, Zoetmulder, Sebbag (bb0170) 2007; 14 Zhang, Fonslow, Shan, Baek, Yates (bb0260) 2013; 113 Solari, Filippi-Chiela, Pilar, Nunes, Gonzalez, Figueiró, Andrade, Klamt (bb0475) 2020; 20 Kerr, Los (bb0070) 1993; 17 Blain, Mucklow, Rawlins, Roberts, Routledge, Shand (bb0315) 1985; 20 Heinhuis, Ros, Kok, Steeghs, Beijnen, Schellens (bb0445) 2019; 30 Solass, Kerb, Mürdter, Giger-Pabst, Strumberg, Tempfer, Zieren, Schwab, Reymond (bb0085) 2014; 21 NCI issues clinical announcement for preferred method of treatment for advanced ovarian cancer (bb0190) 2023 Chen, Song, Wientjes, Au (bb0280) 2003; 9 Kumar, Walle, Bhalla, Walle (bb0255) 1993; 80 Harrison, Fang, Huang (bb0420) 2019; 7 Siegel, Miller, Wagle, Jemal (bb0005) 2023; 73 Zimm, Cleary, Lucas, Weiss, Markman, Andrews, Schiefer, Kim, Horton, Howell (bb0050) 1987; 47 Nagel, Varossieau, Dubbelman, Bokkel Huinink, McVie (bb0040) 1992; 29 Danielsson, Peterson, Caldeira Araújo, Lautenschläger, Gad (bb0385) 2018; 7 Esquivel, Lowy, Markman, Chua, Pelz, Baratti, Baumgartner, Berri, Bretcha-Boix, Deraco, Flores-Ayala, Glehen, Gomez-Portilla, Gonzalez-Moreno, Goodman, Halkia, Kusamura, Moller, Passot, Pocard, Salti, Sardi, Senthil, Spilioitis, Torres-Melero, Turaga, Trout (bb0175) 2014; 21 Bezu, Gomes-de-Silva, Dewitte, Breckpot, Fucikova, Spisek, Galluzzi, Kepp, Kroemer (bb0455) 2015; 6 Pfirschke, Engblom, Rickelt, Cortez-Retamozo, Garris, Pucci, Yamazaki, Poirier-Colame, Newton, Redouane, Lin, Wojtkiewicz, Iwamoto, Mino-Kenudson, Huynh, Hynes, Freeman, Kroemer, Zitvogel, Weissleder, Pittet (bb0450) 2016; 44 Verwaal, van Ruth, de Bree, van Sloothen, van Tinteren, Boot, Zoetmulder (bb0100) 2003; 21 Alberts, Liu, Hannigan, O’Toole, Williams, Young, Franklin, Clarke-Pearson, Malviya, DuBeshter (bb0120) 1996; 335 Musteata (bb0325) 2011; 3 Song, Hsu, Au (bb0300) 1996; 85 Wang, Tao, Jia, Wang, Jiang, Du (bb0340) 2021; 14 Plasma proteome database (bb0265) 2017 Ma, Discher, Finkel (bb0425) 2012; 3 Cristea, Frankel, Synold, Rivkin, Lim, Chung, Chao, Wakabayashi, Paz, Han, Lin, Leong, Hakim, Carroll, Prakash, Dellinger, Park, Morgan (bb0365) 2019; 83 Dobrokhotov, Samsonov, Sokabe, Hirata (bb0400) 2018; 7 van Driel, Koole, Sikorska, Schagen van Leeuwen, Schreuder, Hermans, de Hingh, Arts, Massuger, Aalbers, Verwaal, Kieffer, Vijver, Aaronson, Sonke (bb0185) 2018; 378 Los, Verdegaal, Mutsaers, McVie (bb0195) 1991; 28 Monk, Chan (bb0160) 2017; 28 NCI clinical announcement on intraperitoneal chemotherapy in ovarian cancer (bb0150) 2006 Williamson, Johnson, Maulhardt, Moore, McMeekin, Schulz, Reed, Roby, Mackay, Smith, Weir, Wick, Markman, diZerega, Baltezor, Espinosa, Decedue (bb0360) 2015; 75 Boudinot, Jusko (bb0295) 1984; 73 Spiliotis, Halkia, Kalantzi, Giassas, Lianos, Efstathiou, Sugarbaker (bb0165) 2015; 20 Kai, Drain, Weaver (bb0395) 2019; 49 Highley, Harper, Harper, Dumez, Guetens, Boeck, Prenen, Schrijvers, Maes, Bruijn (bb0345) 2006; 2 Los, Mutsaers, Lenglet, Baldew, McVie (bb0200) 1990; 25 Jin, Tamzalit, Chaudhuri, Black, Huse, Kam (bb0415) 2019; 116 Tewari, Java, Salani, Armstrong, Markman, Herzog, Monk, Chan (bb0130) 2015; 33 Kosanam, Makawita, Judd, Newman, Diamandis (bb0350) 2011; 11 Obeid, Tesniere, Ghiringhelli, Fimia, Apetoh, Perfettini, Castedo, Mignot, Panaretakis, Casares, Metivier, Larochette, Ciccosanti, Piacentini, Zitvogel, Kroemer (bb0430) 2007; 13 Walker, Brady, Wenzel, Fleming, Huang, DiSilvestro, Fujiwara, Alberts, Zheng, Tewari, Cohn, Powell, Van Le, Davidson, Gray, Rose, Aghajanian, Myers, Alvarez Secord, Rubin, Mannel (bb0145) 2019; 37 VENNY (bb0275) 2007 Walker, Mojares, Del Rio Hernandez (bb0405) 2018; 19 White, Kothari, Ikoma, Murphy, Song, Ajani, Mansfield, Badgwell (bb0215) 2020; 27 Coates, Bush, Aspin (bb0230) 1973; 107 Markman, Rowinsky, Hakes, Reichman, Jones, Lewis, Rubin, Curtin, Barakat, Phillips, Hurowitz, Almadrones, Hoskins (bb0060) 1992; 10 Ceelen, Sandra, de Sande, Graversen, Mortensen, Vermeulen, Gasthuys, Reynders, Cosyns, Hoorens, Willaert (bb0095) 2022; 82 Neuwirth, Alexander, Karakousis (bb0035) 2016; 7 Burg, Timmermans, van der Aa, Boll, Rovers, de Hingh, van Altena (bb0020) 2020; 31 Quenet, Elias, Roca, Goere, Ghouti, Pocard, Facy, Arvieux, Lorimier, Pezet, Marchal, Loi, Meeus, De Forges, Stanbury, Paineau, Glehen (bb0135) 2018; 36 Walker, Brady, DiSilvestro, Fujiwara, Alberts, Zheng, Tewari, Cohn, Powell, Van Le, Rubin, Davidson, Gray, Waggoner, Myers, Aghajanian, Secord, Mannel (bb0140) 2016 Khalil, Al-Humadi (bb0320) 2020; 12 Elias, Gilly, Boutitie, Quenet, Bereder, Mansvelt, Lorimier, Dube, Glehen (bb0180) 2010; 28 Barakat, Sabbatini, Bhaskaran, Revzin, Smith, Venkatraman, Aghajanian, Hensley, Soignet, Brown, Soslow, Markman, Hoskins, Spriggs (bb0125) 2002; 20 Markman, Reichman, Hakes, Barakat, Curtin, Rubin, Jones, Lewis, Almadrones, Hoskins (bb0210) 1992; 118 Chan, Lu, Wientjes, Au (bb0240) 2022; 29 Oresta, Pozzi, Braga, Hurle, Lazzeri, Colombo, Frego, Erreni, Faccani, Elefante, Barcella, Guazzoni, Rescigno (bb0480) 2021; 13 Markman, Hakes, Reichman, Hoskins, Rubin, Jones, Almadones, Lewis (bb0065) 1989; 62 del Castillo, Warshaw (bb0015) 1993; 40 Gadducci, Carnino, Chiara, Brunetti, Tanganelli, Romanini, Bruzzone, Conte (bb0105) 2000; 76 Van de Sande, Cosyns, Willaert, Ceelen (bb0010) 2020; 27 Yurttas, Hoffmann, Tolios, Haen, Schwab, Königsrainer, Königsrainer, Beckert, Löffler (bb0075) 2018; 7 Lima, MacKichan, Libertin, Sabino (bb0290) 1983; 11 Blagg, Liedtke, Batjer, Racoosin, Sawyer, Wick, Lawson, Wilkens (bb0310) 1993; 21 Emens, Middleton (bb0470) 2015; 3 Song, Au (bb0305) 1995; 663 Bailly, Thuru, Quesnel (bb0440) 2020; 2 Kranenburg, van der Speeten, de Hingh (bb0030) 2021; 11 Ishigami, Fujiwara, Fukushima, Nashimoto, Yabusaki, Imano, Imamoto, Kodera, Uenosono, Amagai, Kadowaki, Miwa, Yamaguchi, Yamaguchi, Miyaji, Kitayama (bb0220) 2018; 36 Ayad, Kaushik, Weaver (bb0390) 2019; 374 Graversen, Detlefsen, Bjerregaard, Fristrup, Pfeiffer, Mortensen (bb0080) 2018; 10 Yamaguchi, Kaneko, Takahashi, Kagaya, Takagi, Matsumoto, Kurashina, Saito, Hosoya, Sata, Kitayama (bb0225) 2023 ClinicalTrials.gov (bb0245) 2022 Luczak, Marczak, Stobiecki (bb0270) 2014; 9 Markman, Reichman, Hakes, Rubin, Lewis, Jones, Barakat, Curtin, Almadrones, Hoskins (bb0205) 1993; 50 Zhang (10.1016/j.jconrel.2023.08.017_bb0260) 2013; 113 Kosanam (10.1016/j.jconrel.2023.08.017_bb0350) 2011; 11 Blagg (10.1016/j.jconrel.2023.08.017_bb0310) 1993; 21 Kranenburg (10.1016/j.jconrel.2023.08.017_bb0030) 2021; 11 Wang (10.1016/j.jconrel.2023.08.017_bb0340) 2021; 14 Feldman (10.1016/j.jconrel.2023.08.017_bb0235) 1972; 32 Chen (10.1016/j.jconrel.2023.08.017_bb0280) 2003; 9 Ayad (10.1016/j.jconrel.2023.08.017_bb0390) 2019; 374 Blain (10.1016/j.jconrel.2023.08.017_bb0315) 1985; 20 Emens (10.1016/j.jconrel.2023.08.017_bb0470) 2015; 3 Burg (10.1016/j.jconrel.2023.08.017_bb0020) 2020; 31 Markman (10.1016/j.jconrel.2023.08.017_bb0210) 1992; 118 NCI clinical announcement on intraperitoneal chemotherapy in ovarian cancer (10.1016/j.jconrel.2023.08.017_bb0150) Ma (10.1016/j.jconrel.2023.08.017_bb0425) 2012; 3 Markman (10.1016/j.jconrel.2023.08.017_bb0060) 1992; 10 NCI issues clinical announcement for preferred method of treatment for advanced ovarian cancer (10.1016/j.jconrel.2023.08.017_bb0190) Bezu (10.1016/j.jconrel.2023.08.017_bb0455) 2015; 6 Solass (10.1016/j.jconrel.2023.08.017_bb0085) 2014; 21 Gadducci (10.1016/j.jconrel.2023.08.017_bb0105) 2000; 76 Knemeyer (10.1016/j.jconrel.2023.08.017_bb0285) 1999; 44 Siegel (10.1016/j.jconrel.2023.08.017_bb0005) 2023; 73 Armstrong (10.1016/j.jconrel.2023.08.017_bb0110) 2006; 354 Danielsson (10.1016/j.jconrel.2023.08.017_bb0385) 2018; 7 Saitakis (10.1016/j.jconrel.2023.08.017_bb0410) 2017; 6 Lima (10.1016/j.jconrel.2023.08.017_bb0290) 1983; 11 Tewari (10.1016/j.jconrel.2023.08.017_bb0130) 2015; 33 Harrison (10.1016/j.jconrel.2023.08.017_bb0420) 2019; 7 Quenet (10.1016/j.jconrel.2023.08.017_bb0135) 2018; 36 Reymond (10.1016/j.jconrel.2023.08.017_bb0090) 2015 Markman (10.1016/j.jconrel.2023.08.017_bb0115) 2001; 19 Kumar (10.1016/j.jconrel.2023.08.017_bb0255) 1993; 80 Solari (10.1016/j.jconrel.2023.08.017_bb0475) 2020; 20 Kai (10.1016/j.jconrel.2023.08.017_bb0395) 2019; 49 Graversen (10.1016/j.jconrel.2023.08.017_bb0080) 2018; 10 Coates (10.1016/j.jconrel.2023.08.017_bb0230) 1973; 107 Chan (10.1016/j.jconrel.2023.08.017_bb0240) 2022; 29 Highley (10.1016/j.jconrel.2023.08.017_bb0345) 2006; 2 Esquivel (10.1016/j.jconrel.2023.08.017_bb0170) 2007; 14 Song (10.1016/j.jconrel.2023.08.017_bb0300) 1996; 85 Musteata (10.1016/j.jconrel.2023.08.017_bb0325) 2011; 3 Alberts (10.1016/j.jconrel.2023.08.017_bb0120) 1996; 335 Verwaal (10.1016/j.jconrel.2023.08.017_bb0100) 2003; 21 Esquivel (10.1016/j.jconrel.2023.08.017_bb0175) 2014; 21 Buscher (10.1016/j.jconrel.2023.08.017_bb0335) 2014; 6 Obeid (10.1016/j.jconrel.2023.08.017_bb0430) 2007; 13 White (10.1016/j.jconrel.2023.08.017_bb0215) 2020; 27 Dasgupta (10.1016/j.jconrel.2023.08.017_bb0380) 2019; 294 Williamson (10.1016/j.jconrel.2023.08.017_bb0360) 2015; 75 Tu (10.1016/j.jconrel.2023.08.017_bb0460) 1998; 4 Jin (10.1016/j.jconrel.2023.08.017_bb0415) 2019; 116 Walker (10.1016/j.jconrel.2023.08.017_bb0140) 2016 Bailly (10.1016/j.jconrel.2023.08.017_bb0440) 2020; 2 Neuwirth (10.1016/j.jconrel.2023.08.017_bb0035) 2016; 7 Walker (10.1016/j.jconrel.2023.08.017_bb0405) 2018; 19 Walker (10.1016/j.jconrel.2023.08.017_bb0145) 2019; 37 Markman (10.1016/j.jconrel.2023.08.017_bb0065) 1989; 62 Markman (10.1016/j.jconrel.2023.08.017_bb0205) 1993; 50 Cristea (10.1016/j.jconrel.2023.08.017_bb0365) 2019; 83 Yurttas (10.1016/j.jconrel.2023.08.017_bb0075) 2018; 7 Galluzzi (10.1016/j.jconrel.2023.08.017_bb0465) 2015; 28 del Castillo (10.1016/j.jconrel.2023.08.017_bb0015) 1993; 40 Boudinot (10.1016/j.jconrel.2023.08.017_bb0295) 1984; 73 Luczak (10.1016/j.jconrel.2023.08.017_bb0270) 2014; 9 Northcott (10.1016/j.jconrel.2023.08.017_bb0375) 2018; 6 van Driel (10.1016/j.jconrel.2023.08.017_bb0185) 2018; 378 VENNY (10.1016/j.jconrel.2023.08.017_bb0275) Yamaguchi (10.1016/j.jconrel.2023.08.017_bb0225) 2023 Speyer (10.1016/j.jconrel.2023.08.017_bb0055) 1980; 40 Khalil (10.1016/j.jconrel.2023.08.017_bb0320) 2020; 12 Los (10.1016/j.jconrel.2023.08.017_bb0195) 1991; 28 Chaudhuri (10.1016/j.jconrel.2023.08.017_bb0370) 2018; 118 Nagel (10.1016/j.jconrel.2023.08.017_bb0040) 1992; 29 Monk (10.1016/j.jconrel.2023.08.017_bb0160) 2017; 28 Oresta (10.1016/j.jconrel.2023.08.017_bb0480) 2021; 13 Van de Sande (10.1016/j.jconrel.2023.08.017_bb0010) 2020; 27 Ozols (10.1016/j.jconrel.2023.08.017_bb0155) 1999; 10 Heinhuis (10.1016/j.jconrel.2023.08.017_bb0445) 2019; 30 Kroemer (10.1016/j.jconrel.2023.08.017_bb0435) 2013; 31 Kerr (10.1016/j.jconrel.2023.08.017_bb0070) 1993; 17 Spiliotis (10.1016/j.jconrel.2023.08.017_bb0165) 2015; 20 Dobrokhotov (10.1016/j.jconrel.2023.08.017_bb0400) 2018; 7 Waters (10.1016/j.jconrel.2023.08.017_bb0330) 2008; 97 Ceelen (10.1016/j.jconrel.2023.08.017_bb0095) 2022; 82 ClinicalTrials.gov (10.1016/j.jconrel.2023.08.017_bb0245) Ishigami (10.1016/j.jconrel.2023.08.017_bb0220) 2018; 36 Elias (10.1016/j.jconrel.2023.08.017_bb0180) 2010; 28 Barakat (10.1016/j.jconrel.2023.08.017_bb0125) 2002; 20 Pfirschke (10.1016/j.jconrel.2023.08.017_bb0450) 2016; 44 Elferink (10.1016/j.jconrel.2023.08.017_bb0045) 1988; 21 Los (10.1016/j.jconrel.2023.08.017_bb0200) 1990; 25 Chan (10.1016/j.jconrel.2023.08.017_bb0250) 2023 Song (10.1016/j.jconrel.2023.08.017_bb0305) 1995; 663 Zimm (10.1016/j.jconrel.2023.08.017_bb0050) 1987; 47 Plasma proteome database (10.1016/j.jconrel.2023.08.017_bb0265) |
| References_xml | – volume: 28 start-page: 159 year: 1991 end-page: 165 ident: bb0195 article-title: Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy publication-title: Cancer Chemother. Pharmacol. – volume: 80 start-page: 337 year: 1993 end-page: 344 ident: bb0255 article-title: Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein publication-title: Res. Commun. Chem. Pathol. Pharmacol. – volume: 73 start-page: 774 year: 1984 end-page: 780 ident: bb0295 article-title: Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis publication-title: J. Pharm. Sci. – volume: 21 start-page: 3737 year: 2003 end-page: 3743 ident: bb0100 article-title: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer publication-title: J. Clin. Oncol. – volume: 25 start-page: 389 year: 1990 end-page: 394 ident: bb0200 article-title: Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment publication-title: Cancer Chemother. Pharmacol. – volume: 50 start-page: 100 year: 1993 end-page: 104 ident: bb0205 article-title: Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer publication-title: Gynecol. Oncol. – volume: 40 start-page: 430 year: 1993 end-page: 432 ident: bb0015 article-title: Peritoneal metastases in pancreatic carcinoma publication-title: Hepatogastroenterology – volume: 9 year: 2014 ident: bb0270 article-title: Optimization of plasma sample pretreatment for quantitative analysis using iTRAQ labeling and LC-MALDI-TOF/TOF publication-title: PLoS One – volume: 20 start-page: 474 year: 2020 ident: bb0475 article-title: Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells publication-title: BMC Cancer – volume: 13 start-page: 1 year: 2021 end-page: 15 ident: bb0480 article-title: Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer publication-title: Sci. Transl. Med. – volume: 37 start-page: 1380 year: 2019 end-page: 1390 ident: bb0145 article-title: Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG oncology/gynecologic oncology group study publication-title: J. Clin. Oncol. – volume: 11 start-page: 483 year: 1983 end-page: 498 ident: bb0290 article-title: Influence of volume shifts on drug binding during equilibrium dialysis: correction and attenuation publication-title: J. Pharmacokinet. Biopharm. – volume: 21 start-page: 57 year: 1988 end-page: 60 ident: bb0045 article-title: Pharmacokinetics of carboplatin after intraperitoneal administration publication-title: Cancer Chemother. Pharmacol. – volume: 28 start-page: VIII40 year: 2017 end-page: 45 ident: bb0160 article-title: Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer? publication-title: Ann. Oncol. – volume: 49 start-page: 332 year: 2019 end-page: 346 ident: bb0395 article-title: The extracellular matrix modulates the metastatic journey publication-title: Dev. Cell – year: 2017 ident: bb0265 – volume: 97 start-page: 4586 year: 2008 end-page: 4595 ident: bb0330 article-title: Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding publication-title: J. Pharm. Sci. – volume: 29 start-page: 480 year: 1992 end-page: 484 ident: bb0040 article-title: Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration publication-title: Cancer Chemother. Pharmacol. – volume: 2 start-page: zcaa002 year: 2020 ident: bb0440 article-title: Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times, NAR publication-title: Cancer – volume: 6 start-page: 17 year: 2018 ident: bb0375 article-title: Feeling stress: the mechanics of cancer progression and aggression publication-title: Front. Cell Dev. Biol. – volume: 7 start-page: 18 year: 2016 end-page: 28 ident: bb0035 article-title: Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective publication-title: J. Gastrointest. Oncol. – volume: 11 start-page: 4551 year: 2011 end-page: 4558 ident: bb0350 article-title: Mining the malignant ascites proteome for pancreatic cancer biomarkers publication-title: Proteomics – volume: 85 start-page: 29 year: 1996 end-page: 31 ident: bb0300 article-title: Binding of taxol to plastic and glass containers and protein under in vitro conditions publication-title: J. Pharm. Sci. – volume: 73 start-page: 17 year: 2023 end-page: 48 ident: bb0005 article-title: Cancer statistics, 2023, CA publication-title: Cancer J. Clin. – volume: 28 start-page: 63 year: 2010 end-page: 68 ident: bb0180 article-title: Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study publication-title: J. Clin. Oncol. – volume: 44 start-page: 343 year: 2016 end-page: 354 ident: bb0450 article-title: Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy publication-title: Immunity – volume: 30 start-page: 219 year: 2019 end-page: 235 ident: bb0445 article-title: Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors publication-title: Ann. Oncol. – volume: 118 start-page: 6499 year: 2018 end-page: 6515 ident: bb0370 article-title: Mechanobiology of tumor growth publication-title: Chem. Rev. – volume: 7 year: 2018 ident: bb0075 article-title: Systematic review of variations in Hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal Cancer publication-title: J. Clin. Med. – start-page: 389 year: 2015 end-page: 402 ident: bb0090 article-title: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) publication-title: Intraperitoneal Cancer Therapy: Principles and Practice – volume: 19 start-page: 3028 year: 2018 ident: bb0405 article-title: Role of extracellular matrix in development and cancer progression publication-title: Int. J. Mol. Sci. – volume: 17 start-page: 105 year: 1993 end-page: 122 ident: bb0070 article-title: Pharmacokinetic principles of locoregional chemotherapy publication-title: Cancer Surv. – volume: 82 year: 2022 ident: bb0095 article-title: Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases publication-title: eBioMedicine – volume: 14 start-page: 128 year: 2007 end-page: 133 ident: bb0170 article-title: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology publication-title: Ann. Surg. Oncol. – volume: 12 start-page: 143 year: 2020 end-page: 152 ident: bb0320 article-title: Types of acute phase reactants and their importance in vaccination publication-title: Biomed. Rep. – volume: 32 start-page: 1663 year: 1972 end-page: 1666 ident: bb0235 article-title: The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma publication-title: Cancer Res. – year: 2023 ident: bb0250 article-title: Personalized Intraperitoneal Drug Dosing Based on Paclitaxel Binding to Proteins in Human Peritoneal Ascites Fluid, Advanced Cancer Therapies (ACT) Meeting, San Diego – volume: 19 start-page: 1001 year: 2001 end-page: 1007 ident: bb0115 article-title: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, southwestern oncology group, and eastern cooperative oncology group publication-title: J. Clin. Oncol. – volume: 47 start-page: 1712 year: 1987 end-page: 1716 ident: bb0050 article-title: Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide publication-title: Cancer Res. – volume: 44 start-page: 241 year: 1999 end-page: 248 ident: bb0285 article-title: Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment publication-title: Cancer Chemother. Pharmacol. – year: 2023 ident: bb0025 – volume: 10 start-page: 59 year: 1999 end-page: 64 ident: bb0155 article-title: Intraperitoneal treatment and dose-intense therapy in ovarian cancer publication-title: Ann. Oncol. – year: 2016 ident: bb0140 article-title: A phase III trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and peritoneal carcinoma NCI-supplied agent(s): A GOG/NRG trial (GOG 252) publication-title: 2016 Society of Gynecologic Oncology Annual Meeting, (2016) Late-breaking Abstract 6 – volume: 75 start-page: 1075 year: 2015 end-page: 1087 ident: bb0360 article-title: A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax(R)) in patients with peritoneal malignancies publication-title: Cancer Chemother. Pharmacol. – volume: 6 year: 2017 ident: bb0410 article-title: Different TCR-induced T lymphocyte responses are potentiated by stiffness with variable sensitivity publication-title: eLife – volume: 20 start-page: 694 year: 2002 end-page: 698 ident: bb0125 article-title: Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up publication-title: J. Clin. Oncol. – volume: 378 start-page: 230 year: 2018 end-page: 240 ident: bb0185 article-title: Hyperthermic intraperitoneal chemotherapy in ovarian cancer publication-title: N. Engl. J. Med. – year: 2023 ident: bb0190 – volume: 294 start-page: 17693 year: 2019 end-page: 17706 ident: bb0380 article-title: Control of cellular responses to mechanical cues through YAP/TAZ regulation publication-title: J. Biol. Chem. – volume: 7 start-page: 23 year: 2018 ident: bb0400 article-title: Mechanoregulation and pathology of YAP/TAZ via hippo and non-hippo mechanisms publication-title: Clin. Transl. Med. – volume: 3 start-page: 217 year: 2012 ident: bb0425 article-title: Mechanical force in T cell receptor signal initiation publication-title: Front. Immunol. – volume: 7 start-page: 45 year: 2019 ident: bb0420 article-title: T-cell mechanobiology: force sensation, potentiation, and translation publication-title: Front. Phys. – volume: 27 start-page: 40 year: 2020 end-page: 53 ident: bb0010 article-title: Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review publication-title: Drug Deliv. – volume: 40 start-page: 567 year: 1980 end-page: 572 ident: bb0055 article-title: Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally publication-title: Cancer Res. – volume: 21 start-page: 553 year: 2014 end-page: 559 ident: bb0085 article-title: Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy publication-title: Ann. Surg. Oncol. – volume: 113 start-page: 2343 year: 2013 end-page: 2394 ident: bb0260 article-title: Protein analysis by shotgun/bottom-up proteomics publication-title: Chem. Rev. – volume: 6 start-page: 187 year: 2015 ident: bb0455 article-title: Combinatorial strategies for the induction of immunogenic cell death publication-title: Front. Immunol. – volume: 62 start-page: 393 year: 1989 end-page: 403 ident: bb0065 article-title: Intraperitoneal therapy in the management of ovarian carcinoma publication-title: Yale J. Biol. Med. – volume: 29 start-page: S527 year: 2022 ident: bb0240 article-title: Phase I trial of intraperitoneal paclitaxel-loaded TPM for treatment of peritoneal carcinomatosis publication-title: Ann. Surg. Oncol. – volume: 14 start-page: 104 year: 2021 ident: bb0340 article-title: The protein-binding behavior of platinum anticancer drugs in blood revealed by mass spectrometry publication-title: Pharmaceuticals (Basel) – volume: 27 start-page: 4963 year: 2020 end-page: 4969 ident: bb0215 article-title: Factors associated with resection and survival after laparoscopic HIPEC for peritoneal gastric cancer metastasis publication-title: Ann. Surg. Oncol. – volume: 118 start-page: 235 year: 1992 end-page: 237 ident: bb0210 article-title: Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate publication-title: J. Cancer Res. Clin. Oncol. – volume: 4 start-page: 1193 year: 1998 end-page: 1201 ident: bb0460 article-title: Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer publication-title: Clin. Cancer Res. – volume: 116 start-page: 19835 year: 2019 end-page: 19840 ident: bb0415 article-title: T cell activation and immune synapse organization respond to the microscale mechanics of structured surfaces publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 374 start-page: 20180215 year: 2019 ident: bb0390 article-title: Tissue mechanics, an important regulator of development and disease publication-title: Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. – volume: 21 start-page: 138 year: 1993 end-page: 144 ident: bb0310 article-title: Serum albumin concentration-related health care financing administration quality assurance criterion is method-dependent: revision is necessary publication-title: Am. J. Kidney Dis. – volume: 11 year: 2021 ident: bb0030 article-title: Peritoneal metastases from colorectal cancer: defining and addressing the challenges publication-title: Front. Oncol. – volume: 20 start-page: S64 year: 2015 end-page: S70 ident: bb0165 article-title: Mapping the location of peritoneal metastases using the peritoneal cancer index and the correlation with overall survival: a retrospective study publication-title: J. BUON – year: 2007 ident: bb0275 article-title: An Interactive Tool for Comparing Lists with Venn Diagrams – volume: 33 start-page: 1460 year: 2015 end-page: 1466 ident: bb0130 article-title: Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study publication-title: J. Clin. Oncol. – volume: 36 year: 2018 ident: bb0135 article-title: A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7 publication-title: J. Clin. Oncol. – volume: 3 start-page: 436 year: 2015 end-page: 443 ident: bb0470 article-title: The interplay of immunotherapy and chemotherapy: harnessing potential synergies, Cancer publication-title: Immunol. Res. – volume: 31 start-page: 51 year: 2013 end-page: 72 ident: bb0435 article-title: Immunogenic cell death in cancer therapy publication-title: Annu. Rev. Immunol. – year: 2006 ident: bb0150 – year: 2023 ident: bb0225 article-title: Conversion surgery after intraperitoneal paclitaxel combined with systemic oxaliplatin and oral S-1 (SOX) for patients with peritoneal metastasis from gastric cancer publication-title: Advanced Cancer Therapies (ACT) Meeting, San Diego – volume: 663 start-page: 337 year: 1995 end-page: 344 ident: bb0305 article-title: Isocratic high-performance liquid chromatographic assay of taxol in biological fluids and tissues using automated column switching publication-title: J. Chromatogr. B Biomed. Appl. – volume: 13 start-page: 54 year: 2007 end-page: 61 ident: bb0430 article-title: Calreticulin exposure dictates the immunogenicity of cancer cell death publication-title: Nat. Med. – volume: 20 start-page: 500 year: 1985 end-page: 502 ident: bb0315 article-title: Determinants of plasma alpha 1-acid glycoprotein (AAG) concentrations in health publication-title: Br. J. Clin. Pharmacol. – volume: 36 start-page: 1922 year: 2018 end-page: 1929 ident: bb0220 article-title: Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial publication-title: J. Clin. Oncol. – volume: 3 start-page: 1753 year: 2011 end-page: 1768 ident: bb0325 article-title: Monitoring free drug concentrations: challenges publication-title: Bioanalysis – volume: 9 start-page: 363 year: 2003 end-page: 369 ident: bb0280 article-title: Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel publication-title: Clin. Cancer Res. – volume: 10 year: 2018 ident: bb0080 article-title: Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis publication-title: Ther. Adv. Med. Oncol. – volume: 76 start-page: 157 year: 2000 end-page: 162 ident: bb0105 article-title: Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest publication-title: Gynecol. Oncol. – volume: 21 start-page: 4195 year: 2014 end-page: 4201 ident: bb0175 article-title: The American Society of Peritoneal Surface Malignancies (ASPSM) multiinstitution evaluation of the peritoneal surface disease severity score (PSDSS) in 1,013 patients with colorectal cancer with peritoneal carcinomatosis publication-title: Ann. Surg. Oncol. – volume: 31 year: 2020 ident: bb0020 article-title: Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands publication-title: J. Gynecol. Oncol. – volume: 6 start-page: 673 year: 2014 end-page: 682 ident: bb0335 article-title: Bioanalysis for plasma protein binding studies in drug discovery and drug development: views and recommendations of the European bioanalysis forum publication-title: Bioanalysis – volume: 2 start-page: 293 year: 2006 end-page: 297 ident: bb0345 article-title: The pharmacokinetics of Mitomycin C in the Mitomycin C, Ifosfamide and cisplatin (MIC) regimen publication-title: Int. J. Pharmacol. – volume: 83 start-page: 589 year: 2019 end-page: 598 ident: bb0365 article-title: A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity publication-title: Cancer Chemother. Pharmacol. – volume: 354 start-page: 34 year: 2006 end-page: 43 ident: bb0110 article-title: Intraperitoneal cisplatin and paclitaxel in ovarian cancer publication-title: N. Engl. J. Med. – volume: 107 start-page: 577 year: 1973 end-page: 583 ident: bb0230 article-title: A study of ascites using lymphoscintigraphy with 99m Tc-sulfur colloid publication-title: Radiology – volume: 335 start-page: 1950 year: 1996 end-page: 1955 ident: bb0120 article-title: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer publication-title: N. Engl. J. Med. – year: 2022 ident: bb0245 article-title: Intraperitoneal paclitaxel-loaded TPM for treatment of peritoneal carcinomatosis – volume: 7 start-page: 147 year: 2018 ident: bb0385 article-title: Vimentin diversity in health and disease publication-title: Cells – volume: 10 start-page: 1485 year: 1992 end-page: 1491 ident: bb0060 article-title: Phase I trial of intraperitoneal taxol: a Gynecoloic oncology group study publication-title: J. Clin. Oncol. – volume: 28 start-page: 690 year: 2015 end-page: 714 ident: bb0465 article-title: Immunological effects of conventional chemotherapy and targeted anticancer agents publication-title: Cancer Cell – volume: 2 start-page: 293 year: 2006 ident: 10.1016/j.jconrel.2023.08.017_bb0345 article-title: The pharmacokinetics of Mitomycin C in the Mitomycin C, Ifosfamide and cisplatin (MIC) regimen publication-title: Int. J. Pharmacol. doi: 10.3923/ijp.2006.293.297 – volume: 11 start-page: 483 year: 1983 ident: 10.1016/j.jconrel.2023.08.017_bb0290 article-title: Influence of volume shifts on drug binding during equilibrium dialysis: correction and attenuation publication-title: J. Pharmacokinet. Biopharm. doi: 10.1007/BF01062207 – volume: 663 start-page: 337 year: 1995 ident: 10.1016/j.jconrel.2023.08.017_bb0305 article-title: Isocratic high-performance liquid chromatographic assay of taxol in biological fluids and tissues using automated column switching publication-title: J. Chromatogr. B Biomed. Appl. doi: 10.1016/0378-4347(94)00456-F – volume: 40 start-page: 567 year: 1980 ident: 10.1016/j.jconrel.2023.08.017_bb0055 article-title: Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally publication-title: Cancer Res. – ident: 10.1016/j.jconrel.2023.08.017_bb0150 – volume: 3 start-page: 217 year: 2012 ident: 10.1016/j.jconrel.2023.08.017_bb0425 article-title: Mechanical force in T cell receptor signal initiation publication-title: Front. Immunol. doi: 10.3389/fimmu.2012.00217 – volume: 7 start-page: 18 year: 2016 ident: 10.1016/j.jconrel.2023.08.017_bb0035 article-title: Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective publication-title: J. Gastrointest. Oncol. – year: 2023 ident: 10.1016/j.jconrel.2023.08.017_bb0250 – volume: 29 start-page: 480 year: 1992 ident: 10.1016/j.jconrel.2023.08.017_bb0040 article-title: Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/BF00684852 – volume: 76 start-page: 157 year: 2000 ident: 10.1016/j.jconrel.2023.08.017_bb0105 article-title: Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest publication-title: Gynecol. Oncol. doi: 10.1006/gyno.1999.5677 – volume: 21 start-page: 3737 year: 2003 ident: 10.1016/j.jconrel.2023.08.017_bb0100 article-title: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2003.04.187 – volume: 14 start-page: 128 year: 2007 ident: 10.1016/j.jconrel.2023.08.017_bb0170 article-title: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-006-9185-7 – volume: 21 start-page: 138 year: 1993 ident: 10.1016/j.jconrel.2023.08.017_bb0310 article-title: Serum albumin concentration-related health care financing administration quality assurance criterion is method-dependent: revision is necessary publication-title: Am. J. Kidney Dis. doi: 10.1016/S0272-6386(12)81084-5 – volume: 118 start-page: 6499 year: 2018 ident: 10.1016/j.jconrel.2023.08.017_bb0370 article-title: Mechanobiology of tumor growth publication-title: Chem. Rev. doi: 10.1021/acs.chemrev.8b00042 – volume: 13 start-page: 54 year: 2007 ident: 10.1016/j.jconrel.2023.08.017_bb0430 article-title: Calreticulin exposure dictates the immunogenicity of cancer cell death publication-title: Nat. Med. doi: 10.1038/nm1523 – volume: 44 start-page: 241 year: 1999 ident: 10.1016/j.jconrel.2023.08.017_bb0285 article-title: Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/s002800050973 – volume: 21 start-page: 4195 year: 2014 ident: 10.1016/j.jconrel.2023.08.017_bb0175 article-title: The American Society of Peritoneal Surface Malignancies (ASPSM) multiinstitution evaluation of the peritoneal surface disease severity score (PSDSS) in 1,013 patients with colorectal cancer with peritoneal carcinomatosis publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-014-3798-z – volume: 20 start-page: 500 year: 1985 ident: 10.1016/j.jconrel.2023.08.017_bb0315 article-title: Determinants of plasma alpha 1-acid glycoprotein (AAG) concentrations in health publication-title: Br. J. Clin. Pharmacol. doi: 10.1111/j.1365-2125.1985.tb05107.x – volume: 14 start-page: 104 year: 2021 ident: 10.1016/j.jconrel.2023.08.017_bb0340 article-title: The protein-binding behavior of platinum anticancer drugs in blood revealed by mass spectrometry publication-title: Pharmaceuticals (Basel) doi: 10.3390/ph14020104 – volume: 19 start-page: 3028 year: 2018 ident: 10.1016/j.jconrel.2023.08.017_bb0405 article-title: Role of extracellular matrix in development and cancer progression publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms19103028 – volume: 9 start-page: 363 year: 2003 ident: 10.1016/j.jconrel.2023.08.017_bb0280 article-title: Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel publication-title: Clin. Cancer Res. – volume: 30 start-page: 219 year: 2019 ident: 10.1016/j.jconrel.2023.08.017_bb0445 article-title: Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors publication-title: Ann. Oncol. doi: 10.1093/annonc/mdy551 – volume: 6 year: 2017 ident: 10.1016/j.jconrel.2023.08.017_bb0410 article-title: Different TCR-induced T lymphocyte responses are potentiated by stiffness with variable sensitivity publication-title: eLife doi: 10.7554/eLife.23190 – volume: 113 start-page: 2343 year: 2013 ident: 10.1016/j.jconrel.2023.08.017_bb0260 article-title: Protein analysis by shotgun/bottom-up proteomics publication-title: Chem. Rev. doi: 10.1021/cr3003533 – volume: 75 start-page: 1075 year: 2015 ident: 10.1016/j.jconrel.2023.08.017_bb0360 article-title: A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax(R)) in patients with peritoneal malignancies publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/s00280-015-2737-4 – volume: 33 start-page: 1460 year: 2015 ident: 10.1016/j.jconrel.2023.08.017_bb0130 article-title: Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.55.9898 – volume: 13 start-page: 1 year: 2021 ident: 10.1016/j.jconrel.2023.08.017_bb0480 article-title: Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aba6110 – volume: 97 start-page: 4586 year: 2008 ident: 10.1016/j.jconrel.2023.08.017_bb0330 article-title: Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding publication-title: J. Pharm. Sci. doi: 10.1002/jps.21317 – volume: 10 start-page: 59 issue: Suppl. 1 year: 1999 ident: 10.1016/j.jconrel.2023.08.017_bb0155 article-title: Intraperitoneal treatment and dose-intense therapy in ovarian cancer publication-title: Ann. Oncol. doi: 10.1016/S0923-7534(20)31486-1 – volume: 21 start-page: 553 year: 2014 ident: 10.1016/j.jconrel.2023.08.017_bb0085 article-title: Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-013-3213-1 – volume: 7 start-page: 147 year: 2018 ident: 10.1016/j.jconrel.2023.08.017_bb0385 article-title: Vimentin diversity in health and disease publication-title: Cells doi: 10.3390/cells7100147 – volume: 47 start-page: 1712 year: 1987 ident: 10.1016/j.jconrel.2023.08.017_bb0050 article-title: Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide publication-title: Cancer Res. – volume: 9 year: 2014 ident: 10.1016/j.jconrel.2023.08.017_bb0270 article-title: Optimization of plasma sample pretreatment for quantitative analysis using iTRAQ labeling and LC-MALDI-TOF/TOF publication-title: PLoS One doi: 10.1371/journal.pone.0101694 – volume: 36 year: 2018 ident: 10.1016/j.jconrel.2023.08.017_bb0135 article-title: A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.18_suppl.LBA3503 – volume: 80 start-page: 337 year: 1993 ident: 10.1016/j.jconrel.2023.08.017_bb0255 article-title: Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein publication-title: Res. Commun. Chem. Pathol. Pharmacol. – volume: 20 start-page: S64 issue: Suppl. 1 year: 2015 ident: 10.1016/j.jconrel.2023.08.017_bb0165 article-title: Mapping the location of peritoneal metastases using the peritoneal cancer index and the correlation with overall survival: a retrospective study publication-title: J. BUON – volume: 107 start-page: 577 year: 1973 ident: 10.1016/j.jconrel.2023.08.017_bb0230 article-title: A study of ascites using lymphoscintigraphy with 99m Tc-sulfur colloid publication-title: Radiology doi: 10.1148/107.3.577 – volume: 116 start-page: 19835 year: 2019 ident: 10.1016/j.jconrel.2023.08.017_bb0415 article-title: T cell activation and immune synapse organization respond to the microscale mechanics of structured surfaces publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1906986116 – volume: 73 start-page: 17 year: 2023 ident: 10.1016/j.jconrel.2023.08.017_bb0005 article-title: Cancer statistics, 2023, CA publication-title: Cancer J. Clin. doi: 10.3322/caac.21763 – volume: 27 start-page: 40 year: 2020 ident: 10.1016/j.jconrel.2023.08.017_bb0010 article-title: Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review publication-title: Drug Deliv. doi: 10.1080/10717544.2019.1704945 – volume: 28 start-page: 159 year: 1991 ident: 10.1016/j.jconrel.2023.08.017_bb0195 article-title: Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/BF00685503 – volume: 118 start-page: 235 year: 1992 ident: 10.1016/j.jconrel.2023.08.017_bb0210 article-title: Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate publication-title: J. Cancer Res. Clin. Oncol. doi: 10.1007/BF01410140 – volume: 20 start-page: 474 year: 2020 ident: 10.1016/j.jconrel.2023.08.017_bb0475 article-title: Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells publication-title: BMC Cancer doi: 10.1186/s12885-020-06964-5 – volume: 49 start-page: 332 year: 2019 ident: 10.1016/j.jconrel.2023.08.017_bb0395 article-title: The extracellular matrix modulates the metastatic journey publication-title: Dev. Cell doi: 10.1016/j.devcel.2019.03.026 – volume: 3 start-page: 1753 year: 2011 ident: 10.1016/j.jconrel.2023.08.017_bb0325 article-title: Monitoring free drug concentrations: challenges publication-title: Bioanalysis doi: 10.4155/bio.11.187 – volume: 40 start-page: 430 year: 1993 ident: 10.1016/j.jconrel.2023.08.017_bb0015 article-title: Peritoneal metastases in pancreatic carcinoma publication-title: Hepatogastroenterology – volume: 50 start-page: 100 year: 1993 ident: 10.1016/j.jconrel.2023.08.017_bb0205 article-title: Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer publication-title: Gynecol. Oncol. doi: 10.1006/gyno.1993.1171 – volume: 7 start-page: 45 year: 2019 ident: 10.1016/j.jconrel.2023.08.017_bb0420 article-title: T-cell mechanobiology: force sensation, potentiation, and translation publication-title: Front. Phys. doi: 10.3389/fphy.2019.00045 – volume: 6 start-page: 187 year: 2015 ident: 10.1016/j.jconrel.2023.08.017_bb0455 article-title: Combinatorial strategies for the induction of immunogenic cell death publication-title: Front. Immunol. – volume: 44 start-page: 343 year: 2016 ident: 10.1016/j.jconrel.2023.08.017_bb0450 article-title: Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy publication-title: Immunity doi: 10.1016/j.immuni.2015.11.024 – volume: 19 start-page: 1001 year: 2001 ident: 10.1016/j.jconrel.2023.08.017_bb0115 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2001.19.4.1001 – volume: 82 year: 2022 ident: 10.1016/j.jconrel.2023.08.017_bb0095 article-title: Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases publication-title: eBioMedicine doi: 10.1016/j.ebiom.2022.104151 – volume: 28 start-page: VIII40 year: 2017 ident: 10.1016/j.jconrel.2023.08.017_bb0160 article-title: Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer? publication-title: Ann. Oncol. doi: 10.1093/annonc/mdx451 – volume: 10 start-page: 1485 year: 1992 ident: 10.1016/j.jconrel.2023.08.017_bb0060 article-title: Phase I trial of intraperitoneal taxol: a Gynecoloic oncology group study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.1992.10.9.1485 – ident: 10.1016/j.jconrel.2023.08.017_bb0190 – volume: 3 start-page: 436 year: 2015 ident: 10.1016/j.jconrel.2023.08.017_bb0470 article-title: The interplay of immunotherapy and chemotherapy: harnessing potential synergies, Cancer publication-title: Immunol. Res. – volume: 4 start-page: 1193 year: 1998 ident: 10.1016/j.jconrel.2023.08.017_bb0460 article-title: Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer publication-title: Clin. Cancer Res. – year: 2016 ident: 10.1016/j.jconrel.2023.08.017_bb0140 article-title: A phase III trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and peritoneal carcinoma NCI-supplied agent(s): A GOG/NRG trial (GOG 252) – volume: 2 start-page: zcaa002 year: 2020 ident: 10.1016/j.jconrel.2023.08.017_bb0440 article-title: Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times, NAR publication-title: Cancer – volume: 27 start-page: 4963 year: 2020 ident: 10.1016/j.jconrel.2023.08.017_bb0215 article-title: Factors associated with resection and survival after laparoscopic HIPEC for peritoneal gastric cancer metastasis publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-020-08842-7 – volume: 11 year: 2021 ident: 10.1016/j.jconrel.2023.08.017_bb0030 article-title: Peritoneal metastases from colorectal cancer: defining and addressing the challenges publication-title: Front. Oncol. doi: 10.3389/fonc.2021.650098 – volume: 374 start-page: 20180215 year: 2019 ident: 10.1016/j.jconrel.2023.08.017_bb0390 article-title: Tissue mechanics, an important regulator of development and disease publication-title: Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. – volume: 17 start-page: 105 year: 1993 ident: 10.1016/j.jconrel.2023.08.017_bb0070 article-title: Pharmacokinetic principles of locoregional chemotherapy publication-title: Cancer Surv. – volume: 37 start-page: 1380 year: 2019 ident: 10.1016/j.jconrel.2023.08.017_bb0145 article-title: Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG oncology/gynecologic oncology group study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.18.01568 – volume: 32 start-page: 1663 year: 1972 ident: 10.1016/j.jconrel.2023.08.017_bb0235 article-title: The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma publication-title: Cancer Res. – volume: 7 year: 2018 ident: 10.1016/j.jconrel.2023.08.017_bb0075 article-title: Systematic review of variations in Hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal Cancer publication-title: J. Clin. Med. doi: 10.3390/jcm7120567 – volume: 20 start-page: 694 year: 2002 ident: 10.1016/j.jconrel.2023.08.017_bb0125 article-title: Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2002.20.3.694 – volume: 25 start-page: 389 year: 1990 ident: 10.1016/j.jconrel.2023.08.017_bb0200 article-title: Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/BF00686048 – volume: 83 start-page: 589 year: 2019 ident: 10.1016/j.jconrel.2023.08.017_bb0365 article-title: A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/s00280-019-03767-9 – volume: 28 start-page: 63 year: 2010 ident: 10.1016/j.jconrel.2023.08.017_bb0180 article-title: Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.23.9285 – volume: 31 year: 2020 ident: 10.1016/j.jconrel.2023.08.017_bb0020 article-title: Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands publication-title: J. Gynecol. Oncol. doi: 10.3802/jgo.2020.31.e58 – volume: 85 start-page: 29 year: 1996 ident: 10.1016/j.jconrel.2023.08.017_bb0300 article-title: Binding of taxol to plastic and glass containers and protein under in vitro conditions publication-title: J. Pharm. Sci. doi: 10.1021/js950286j – volume: 12 start-page: 143 year: 2020 ident: 10.1016/j.jconrel.2023.08.017_bb0320 article-title: Types of acute phase reactants and their importance in vaccination publication-title: Biomed. Rep. – start-page: 389 year: 2015 ident: 10.1016/j.jconrel.2023.08.017_bb0090 article-title: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) – volume: 294 start-page: 17693 year: 2019 ident: 10.1016/j.jconrel.2023.08.017_bb0380 article-title: Control of cellular responses to mechanical cues through YAP/TAZ regulation publication-title: J. Biol. Chem. doi: 10.1074/jbc.REV119.007963 – volume: 21 start-page: 57 year: 1988 ident: 10.1016/j.jconrel.2023.08.017_bb0045 article-title: Pharmacokinetics of carboplatin after intraperitoneal administration publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/BF00262740 – volume: 36 start-page: 1922 year: 2018 ident: 10.1016/j.jconrel.2023.08.017_bb0220 article-title: Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.77.8613 – volume: 31 start-page: 51 year: 2013 ident: 10.1016/j.jconrel.2023.08.017_bb0435 article-title: Immunogenic cell death in cancer therapy publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev-immunol-032712-100008 – ident: 10.1016/j.jconrel.2023.08.017_bb0275 – ident: 10.1016/j.jconrel.2023.08.017_bb0265 – volume: 62 start-page: 393 year: 1989 ident: 10.1016/j.jconrel.2023.08.017_bb0065 article-title: Intraperitoneal therapy in the management of ovarian carcinoma publication-title: Yale J. Biol. Med. – volume: 335 start-page: 1950 year: 1996 ident: 10.1016/j.jconrel.2023.08.017_bb0120 article-title: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJM199612263352603 – volume: 28 start-page: 690 year: 2015 ident: 10.1016/j.jconrel.2023.08.017_bb0465 article-title: Immunological effects of conventional chemotherapy and targeted anticancer agents publication-title: Cancer Cell doi: 10.1016/j.ccell.2015.10.012 – year: 2023 ident: 10.1016/j.jconrel.2023.08.017_bb0225 article-title: Conversion surgery after intraperitoneal paclitaxel combined with systemic oxaliplatin and oral S-1 (SOX) for patients with peritoneal metastasis from gastric cancer – volume: 29 start-page: S527 year: 2022 ident: 10.1016/j.jconrel.2023.08.017_bb0240 article-title: Phase I trial of intraperitoneal paclitaxel-loaded TPM for treatment of peritoneal carcinomatosis publication-title: Ann. Surg. Oncol. – volume: 378 start-page: 230 year: 2018 ident: 10.1016/j.jconrel.2023.08.017_bb0185 article-title: Hyperthermic intraperitoneal chemotherapy in ovarian cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1708618 – volume: 7 start-page: 23 year: 2018 ident: 10.1016/j.jconrel.2023.08.017_bb0400 article-title: Mechanoregulation and pathology of YAP/TAZ via hippo and non-hippo mechanisms publication-title: Clin. Transl. Med. doi: 10.1186/s40169-018-0202-9 – volume: 73 start-page: 774 year: 1984 ident: 10.1016/j.jconrel.2023.08.017_bb0295 article-title: Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis publication-title: J. Pharm. Sci. doi: 10.1002/jps.2600730617 – ident: 10.1016/j.jconrel.2023.08.017_bb0245 – volume: 10 year: 2018 ident: 10.1016/j.jconrel.2023.08.017_bb0080 article-title: Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis publication-title: Ther. Adv. Med. Oncol. doi: 10.1177/1758835918777036 – volume: 11 start-page: 4551 year: 2011 ident: 10.1016/j.jconrel.2023.08.017_bb0350 article-title: Mining the malignant ascites proteome for pancreatic cancer biomarkers publication-title: Proteomics doi: 10.1002/pmic.201100264 – volume: 6 start-page: 17 year: 2018 ident: 10.1016/j.jconrel.2023.08.017_bb0375 article-title: Feeling stress: the mechanics of cancer progression and aggression publication-title: Front. Cell Dev. Biol. doi: 10.3389/fcell.2018.00017 – volume: 354 start-page: 34 year: 2006 ident: 10.1016/j.jconrel.2023.08.017_bb0110 article-title: Intraperitoneal cisplatin and paclitaxel in ovarian cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa052985 – volume: 6 start-page: 673 year: 2014 ident: 10.1016/j.jconrel.2023.08.017_bb0335 article-title: Bioanalysis for plasma protein binding studies in drug discovery and drug development: views and recommendations of the European bioanalysis forum publication-title: Bioanalysis doi: 10.4155/bio.13.338 |
| SSID | ssj0005347 |
| Score | 2.4351358 |
| Snippet | Cytoreductive surgery (CRS) has emerged as a survival-extending treatment of peritoneal metastasis (PM); recent advances include using intraperitoneal... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 717 |
| SubjectTerms | Antineoplastic Combined Chemotherapy Protocols ascites Ascites - drug therapy Colorectal Neoplasms - drug therapy Combined Modality Therapy Cytoreductive surgery dialysis Drug binding to ascites proteins drug therapy drugs fever glycoproteins human serum albumin Humans Hyperthermia, Induced Hyperthermic intraperitoneal chemotherapy Intraperitoneal chemotherapy medicinal properties metastasis neoplasms Paclitaxel Paclitaxel - therapeutic use patients Peritoneal carcinomatosis Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - secondary Pharmaceutical Preparations Pharmaceutical Research pharmacodynamics pharmacokinetics protein binding Proteomics surgery Tandem Mass Spectrometry |
| Title | Surgical management of peritoneal metastasis: Opportunities for pharmaceutical research |
| URI | https://dx.doi.org/10.1016/j.jconrel.2023.08.017 https://www.ncbi.nlm.nih.gov/pubmed/37574051 https://www.proquest.com/docview/2850715505 https://www.proquest.com/docview/3040442173 https://pubmed.ncbi.nlm.nih.gov/PMC10560040 |
| Volume | 361 |
| WOSCitedRecordID | wos001067360500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-4995 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005347 issn: 0168-3659 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Nb9MwFLe6jQMXND5XBpORUC8sJYnT2OU2oU4Dqq4SmejNShxXbVXS0jbTduB_5_kjycJWbRy4RJVj147fz8_Pfl8IvSedIBYySZw0DJkTCCGcJHUDJ5VESpIwb-xqR-E-HQzYaNQdNhq_C1-YyznNMnZ11V3-V1JDGRBbuc7-A7nLP4UC-A1EhyeQHZ4PIvz3fGW42c_SskWbNUPfKvC29hbZxCAUrqfaHO58qUTwPNOhVbXV4XJSu-e28YAmW-RYa-w-l6lOwHJT26N8LWeGD1nz_CqVVz_XepGysnJzsBYo88X6w1llchzlq9hc_36briyY7T2FT0pDrIK1MkocOF8ZHba8o8zyY2Kis1uOSo1r5y1Oby4dZu0ZfCV8XVt1qYOxmvr1yNqDc3560e_zqDeKWstfjko6ppTzNgPLDtrzaacLTHHv5Etv9LWyESI6Q105zMoF7OOdPW8Tbm4fXv62wb0h1ET76ImlIj4xKHqKGjJ7hlpDQ__rYxxV3nnrY9zCwyrQ-fVz9KOAGq6ghhdjXEENV1D7hGtAwwA0XAcaLoD2Al2c9qLPZ45N1OGIjuttHAqCFsjticcEYQlIRd1xEoeuL8MUVjslsIvEPg1CqaIZChCWAhZ0WOgKOCyzMew5L9FuBsM6QHjMmEdipS3uJiBrxkkiUp2GgPkE5oo0UVDMMBc2ir1KpjLnhbnijFvCcEUYrpKserSJ2mWzpQnjcl8DVpCPW1nUyJgcAHhf03cFuTnwaqWAizO5yNfcZ-r0pe4EttchsKsGgQ-z1kSvDETKERPaoXDA8mBwNfCUFVSs-PqbbDrRMePhGBWqDfv1AwZ3iB5XC_gN2t2scvkWPRKXm-l6dYR26Igd2ZXyB8p85Pw |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Surgical+management+of+peritoneal+metastasis%3A+Opportunities+for+pharmaceutical+research&rft.jtitle=Journal+of+controlled+release&rft.au=Wientjes%2C+Michael+G&rft.au=Lu%2C+Ze&rft.au=Chan%2C+Carlos+H+F&rft.au=Turaga%2C+Kiran&rft.date=2023-09-01&rft.issn=1873-4995&rft.eissn=1873-4995&rft.volume=361&rft.spage=717&rft_id=info:doi/10.1016%2Fj.jconrel.2023.08.017&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0168-3659&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0168-3659&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0168-3659&client=summon |